Billings Clinic
Especially For:

Clinical Trials

Title   Carcinoid Tumors: Advanced with Poor Prognosis
Description   A Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC#704865) in Advanced, Poor Prognosis Carcinoid Patients.
IRB Number   SWOG S0518
Category   Gastrointestinal
Inclusion/Notes   Must be High Risk disease poorly differentiated neuroendocrine, high-grade neuroendocrine carcinoma, adenocarcinoid, or goblet cell are not eligible. Must have a SPECT octreotride scan which requires 1.5 weeks notice to order with radiology and must be approved by insurance.

Please contact Tricia Montgomery, RN for additional inclusion/exclusion criteria.
Status   Active
Start Date   01/11/2008
Principal Investigator (PI)   Jorge Nieva, MD
Physician Profile   Medical Oncologist
Contact Name   Tricia Montgomery RN
Contact Email
Phone   (406) 435-7483
Fax   (406) 435-7489
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.